Literature DB >> 1801827

Alpha-1 antichymotrypsin is increased in human alveolar macrophages by phorbol myristate acetate or lipopolysaccharide and released from these activated macrophages by glucocorticoid.

T Nagareda1, M Takeda, K Kojima, A Tanaka, N Terada, T Yamasaki, T Nagareda1, H Ueno, K Kotoh.   

Abstract

Alveolar macrophages were obtained from 23 patients and the effects of phorbol myristate acetate (PMA), lipopolysaccharide (LPS), and dexamethasone (DEX) on the proportion of cells with intracellular alpha-1 antichymotrypsin (ACT), and concentrations of ACT in the culture medium were studied in vitro. The alveolar macrophages were obtained by bronchoalveolar lavage at autopsy or from resected lungs at operation and were cultured in suspension for 3 days in medium containing PMA, LPS, DEX, PMA+DEX, or LPS+DEX. Both PMA and LPS significantly increased the percentage of macrophages with intracellular ACT. Dexamethasone did not increase the number of ACT-positive cells and significantly suppressed the increase induced by PMA or LPS, releasing ACT into the culture medium. The release of ACT from macrophages may contribute to the anti-inflammatory effects of corticoids.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1801827     DOI: 10.1002/path.1711650407

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  2 in total

1.  Polymorphism of SERPINE2 gene is associated with pulmonary emphysema in consecutive autopsy cases.

Authors:  Koichi Fujimoto; Shinobu Ikeda; Tomio Arai; Noriko Tanaka; Toshio Kumasaka; Takeo Ishii; Kozui Kida; Masaaki Muramatsu; Motoji Sawabe
Journal:  BMC Med Genet       Date:  2010-11-10       Impact factor: 2.103

2.  Identification of haptoglobin peptide as a novel serum biomarker for lung squamous cell carcinoma by serum proteome and peptidome profiling.

Authors:  Tetsuya Okano; Masahiro Seike; Hidehiko Kuribayashi; Chie Soeno; Takeo Ishii; Kozui Kida; Akihiko Gemma
Journal:  Int J Oncol       Date:  2016-01-11       Impact factor: 5.650

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.